FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378902008> ?p ?o ?g. }

• W4378902008 abstract "Abstract Background New biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) all showed greater clinical benefits in the treatment of patients with rheumatoid arthritis (RA) with high disease activity, but imposed higher costs than standard treatment. This study evaluated the cost-effectiveness of 11 alternative treatment strategies for RA patients with high disease activity whose treatment with three conventional synthetic DMARDs (csDMARDs) failed. Methods A Markov model was constructed using a societal perspective to estimate relevant costs and health outcomes in terms of quality-adjusted life years (QALYs) for a lifetime horizon (100 years), given a 3% annual discount. Alternative treatment strategies including five bDMARDs, two tsDMARDs, and four bsDMARDs in combination with methotrexate (MTX) were compared with the standard of care (SoC), i.e., cyclosporine and azathioprine. Direct and non-medical care costs were estimated by identifying the resources used, then multiplied by the standard costing menu in the year 2022. Utility and transitional probabilities were collected in three advanced tertiary hospitals. A network meta-analysis was used to estimate the efficacy of each treatment. Lifetime cost, QALYs and an incremental cost-effectiveness ratio were calculated and compared to the cost-effectiveness threshold of 160,000 THB per QALY gained (US $4,634, where 1 USD = 34.53 THB in 2022). Probabilistic and one-way sensitivity analyses were performed to estimate parameter uncertainties. Results The bDMARDs, tsDMARDs or bsDMARDs combined with MTX provided 0.09 to 0.33 QALYs gained with additional costs of 550,986 to 2,096,744 THB (US $15,957 to $60,722) compared to the SoC. The ICER ranged from 2.3 to 8.1 million THB per QALY (US $65,935 to $234,996) compared to the SoC. None of these combinations was cost-effective in the Thai context. The results were sensitive to the mortality hazard ratio of patients with high disease activity. Conclusions Combinations of MTX with either bDMARDs, tsDMARDs or bsDMARDs were not economically attractive compared to the standard practice. However, they reduced disease activity and improved patient quality of life. The price negotiation process for these treatments must be conducted to ensure their financial value and affordability before they are included in the pharmaceutical reimbursement list." @default.
• W4378902008 created "2023-06-01" @default.
• W4378902008 creator A5009574970 @default.
• W4378902008 creator A5009946234 @default.
• W4378902008 creator A5014870649 @default.
• W4378902008 creator A5030712947 @default.
• W4378902008 creator A5038666456 @default.
• W4378902008 creator A5039824776 @default.
• W4378902008 creator A5041006807 @default.
• W4378902008 creator A5048383987 @default.
• W4378902008 date "2023-05-31" @default.
• W4378902008 modified "2023-10-08" @default.
• W4378902008 title "Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity" @default.
• W4378902008 cites W1274762127 @default.
• W4378902008 cites W1489182588 @default.
• W4378902008 cites W1858529395 @default.
• W4378902008 cites W2014937111 @default.
• W4378902008 cites W2038593306 @default.
• W4378902008 cites W2090532253 @default.
• W4378902008 cites W2099559598 @default.
• W4378902008 cites W2110177517 @default.
• W4378902008 cites W2120393706 @default.
• W4378902008 cites W2131517206 @default.
• W4378902008 cites W2142004396 @default.
• W4378902008 cites W2148843297 @default.
• W4378902008 cites W2166732840 @default.
• W4378902008 cites W2168250184 @default.
• W4378902008 cites W2190951387 @default.
• W4378902008 cites W2285338650 @default.
• W4378902008 cites W2300189187 @default.
• W4378902008 cites W2911316462 @default.
• W4378902008 cites W2950204659 @default.
• W4378902008 cites W2964956029 @default.
• W4378902008 cites W2968718300 @default.
• W4378902008 cites W2266661241 @default.
• W4378902008 doi "https://doi.org/10.1186/s12913-023-09595-1" @default.
• W4378902008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37259090" @default.
• W4378902008 hasPublicationYear "2023" @default.
• W4378902008 type Work @default.
• W4378902008 citedByCount "0" @default.
• W4378902008 crossrefType "journal-article" @default.
• W4378902008 hasAuthorship W4378902008A5009574970 @default.
• W4378902008 hasAuthorship W4378902008A5009946234 @default.
• W4378902008 hasAuthorship W4378902008A5014870649 @default.
• W4378902008 hasAuthorship W4378902008A5030712947 @default.
• W4378902008 hasAuthorship W4378902008A5038666456 @default.
• W4378902008 hasAuthorship W4378902008A5039824776 @default.
• W4378902008 hasAuthorship W4378902008A5041006807 @default.
• W4378902008 hasAuthorship W4378902008A5048383987 @default.
• W4378902008 hasBestOaLocation W43789020081 @default.
• W4378902008 hasConcept C112930515 @default.
• W4378902008 hasConcept C126322002 @default.
• W4378902008 hasConcept C2777575956 @default.
• W4378902008 hasConcept C3019080777 @default.
• W4378902008 hasConcept C64332521 @default.
• W4378902008 hasConcept C71924100 @default.
• W4378902008 hasConceptScore W4378902008C112930515 @default.
• W4378902008 hasConceptScore W4378902008C126322002 @default.
• W4378902008 hasConceptScore W4378902008C2777575956 @default.
• W4378902008 hasConceptScore W4378902008C3019080777 @default.
• W4378902008 hasConceptScore W4378902008C64332521 @default.
• W4378902008 hasConceptScore W4378902008C71924100 @default.
• W4378902008 hasIssue "1" @default.
• W4378902008 hasLocation W43789020081 @default.
• W4378902008 hasLocation W43789020082 @default.
• W4378902008 hasOpenAccess W4378902008 @default.
• W4378902008 hasPrimaryLocation W43789020081 @default.
• W4378902008 hasRelatedWork W2041279917 @default.
• W4378902008 hasRelatedWork W2082406232 @default.
• W4378902008 hasRelatedWork W2156283049 @default.
• W4378902008 hasRelatedWork W2316954211 @default.
• W4378902008 hasRelatedWork W2326094713 @default.
• W4378902008 hasRelatedWork W2427075784 @default.
• W4378902008 hasRelatedWork W2427452099 @default.
• W4378902008 hasRelatedWork W2761967325 @default.
• W4378902008 hasRelatedWork W3042161981 @default.
• W4378902008 hasRelatedWork W4245782456 @default.
• W4378902008 hasVolume "23" @default.
• W4378902008 isParatext "false" @default.
• W4378902008 isRetracted "false" @default.
• W4378902008 workType "article" @default.